Tdap and Biomarkers of Alzheimer's Disease

Status unconfirmed · Phase 1/Phase 2

Conditions studied: Alzheimer Disease, Late Onset

In brief

Recently, the Tdap (tetanus toxoid, reduced diphtheria toxoid and acellular pertussis) vaccination was added to the list of immunizations associated with lower incidence of dementia. Plasma-based biomarkers for AD are a welcome alternative to expensive and invasive testing for Alzheimer's; these biomarkers include assessment of amyloid and tau and neurofilament light protein that assesses non-specific neurodegeneration. The investigators will test for these biomarkers, as well as some immune parameters, administer Tdap then repeat the blood tests in six months.

Key facts

Study ID

NCT05183516

Run by

Mindful Diagnostics and Therapeutics, LLC

People needed

50

Starts

2023-05-01

Expected to finish

2024-03-31

Last updated by the study team

2022-08-25

Who can join

Age: 50 and older, up to 80. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Immuno- competent
• Out of compliance for Tdap vaccine (none within 10 years).
• Ability of give informed consent.
• SAGE test 17 or greater

You may not qualify if…

• Immuno- compromised
• In compliance for Tdap vaccination (within 10 years).
• Known allergy to components of the Tdap vaccine.
• SAGE test <17

Where it is running

• Mindful Diagnostics and Therapeutics — Eau Claire, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.